These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay. Stammers TA; Coulombe R; Duplessis M; Fazal G; Gagnon A; Garneau M; Goulet S; Jakalian A; LaPlante S; Rancourt J; Thavonekham B; Wernic D; Kukolj G; Beaulieu PL Bioorg Med Chem Lett; 2013 Dec; 23(24):6879-85. PubMed ID: 24176401 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108 [TBL] [Abstract][Full Text] [Related]
5. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors. Yu H; Fang Y; Lu X; Liu Y; Zhang H Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500 [TBL] [Abstract][Full Text] [Related]
6. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870 [TBL] [Abstract][Full Text] [Related]
7. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089 [TBL] [Abstract][Full Text] [Related]
8. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. Patel PD; Patel MR; Kaushik-Basu N; Talele TT J Chem Inf Model; 2008 Jan; 48(1):42-55. PubMed ID: 18076152 [TBL] [Abstract][Full Text] [Related]
9. Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. Nittoli T; Curran K; Insaf S; DiGrandi M; Orlowski M; Chopra R; Agarwal A; Howe AY; Prashad A; Floyd MB; Johnson B; Sutherland A; Wheless K; Feld B; O'Connell J; Mansour TS; Bloom J J Med Chem; 2007 May; 50(9):2108-16. PubMed ID: 17402724 [TBL] [Abstract][Full Text] [Related]
10. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study. Elfiky AA Med Chem; 2019; 15(2):130-137. PubMed ID: 30324891 [TBL] [Abstract][Full Text] [Related]
11. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase. Harikishore A; Li E; Lee JJ; Cho NJ; Yoon HS Mol Divers; 2015 Aug; 19(3):529-39. PubMed ID: 25862642 [TBL] [Abstract][Full Text] [Related]
12. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D- QSAR and molecular docking studies. Cao H; Cao R; Zhang H; Zheng X; Gao D Curr Med Chem; 2008; 15(15):1462-77. PubMed ID: 18537623 [TBL] [Abstract][Full Text] [Related]
14. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors. Elhefnawi M; ElGamacy M; Fares M BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. Beaulieu PL; Coulombe R; Duan J; Fazal G; Godbout C; Hucke O; Jakalian A; Joly MA; Lepage O; Llinàs-Brunet M; Naud J; Poirier M; Rioux N; Thavonekham B; Kukolj G; Stammers TA Bioorg Med Chem Lett; 2013 Jul; 23(14):4132-40. PubMed ID: 23768906 [TBL] [Abstract][Full Text] [Related]
16. A study of the allosteric inhibition of HCV RNA-dependent RNA polymerase and implementing virtual screening for the selection of promising dual-site inhibitors with low resistance potential. Ismail NSM; Elzahabi HSA; Sabry P; Baselious FN; AbdelMalak AS; Hanna F J Recept Signal Transduct Res; 2017 Aug; 37(4):341-354. PubMed ID: 27829320 [TBL] [Abstract][Full Text] [Related]
17. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase. Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679 [TBL] [Abstract][Full Text] [Related]
18. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR. El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392 [TBL] [Abstract][Full Text] [Related]
19. Combined 3D-QSAR, molecular docking and molecular dynamics study on the benzimidazole inhibitors targeting HCV NS5B polymerase. Wang Z; Chen Z; Li J; Huang J; Zheng C; Liu JP J Biomol Struct Dyn; 2020 Mar; 38(4):1071-1082. PubMed ID: 30915896 [TBL] [Abstract][Full Text] [Related]